Recursion Pharmaceuticals Inc Cl A (RXRX)

$3.42 +0.13 (3.95%)
Market Cap 1.80B
Revenue (ttm) 74.68M
Net Income (ttm) -644.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -863.36%
Debt to Equity Ratio 0.01
Volume 14,409,800
Avg Vol 19,958,367
Day's Range N/A - N/A
Shares Out 527.40M
Stochastic %K 37%
Beta 0.97
Analysts Sell
Price Target $6.71

Company Profile

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-12...

Industry: Biotechnology
Sector: Healthcare
Phone: 385 269 0203
Address:
41 South Rio Grande Street, Salt Lake City, United States
Bazzzigar
Bazzzigar Mar. 15 at 8:06 PM
$RXRX HIMS
0 · Reply
DragonAlgo
DragonAlgo Mar. 15 at 2:36 AM
🐉 $RXRX CALL — DragonAlgo® Signal Contract: RXRX CALL Expiry: 2026-04-17 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $0.17 Stop: $0.12 TP1: $0.22 TP2: $0.29 TP3: $0.41 🔗 https://dragonalgo.com
0 · Reply
MakingMoney20
MakingMoney20 Mar. 14 at 5:01 PM
$RXRX Looking to this spring for some great gains as Summer comes to heat things up! Want a watch this Bust out! Recursion! RXRX $$
0 · Reply
JennyRowes
JennyRowes Mar. 14 at 3:26 PM
$GENB $ABSI $RXRX which AI drug dev leader do we think has more chops?? A) Najat Kahn B) Sean McCain C) Mike Nally
0 · Reply
cntrade1
cntrade1 Mar. 14 at 2:12 AM
$RXRX Vanguard scooped up over 3.7 million RXRX shares in Q3 last year, pushing them to about forty million total. ARK added half a million + in that same quarter. They also added another ~1.3 million in February alone.
1 · Reply
Spartangio
Spartangio Mar. 13 at 10:37 PM
$RXRX NVIDIA — Insider Selling History $3.4 BILLION sold by insiders. 161 Form 4s. All sales. Zero buys. For years. Stock: +10,000% 🚀 RXRX bears crying about $5M insider sales
0 · Reply
Brodman
Brodman Mar. 13 at 9:30 PM
$RXRX There are a LOT OF INSIDERS SELLING….A LOT??? That along with Nvidia dumping shares a huge Red Flag…It may be time to get out of Dodge before it really bottoms out. ITS GOING MUCH LOWER!!!!
2 · Reply
Zio_Fauss
Zio_Fauss Mar. 13 at 8:35 PM
$RXRX These doctors and half-baked scientists are sucking up money every month. https://ir.recursion.com/financials-filings/sec-filings?field_nir_sec_date_filed_value=2026&filter_type=&relative_date_range_after=&relative_date_range_before=&exact_date_range_after=&exact_date_range_before=&items_per_page=50#views-exposed-form-widget-sec-filings-table
0 · Reply
cntrade1
cntrade1 Mar. 13 at 8:10 PM
$RXRX
0 · Reply
cntrade1
cntrade1 Mar. 13 at 7:21 PM
$RXRX Recursion’s got a solid lineup of catalysts ahead, NVIDIA GTC next week (March 16-19) talking AI drug labs, early Phase 1 safety/PK updates rolling out: REC-1245 (RBM39 degrader) in the first half, others like REC-617 and REC-3565 into next year.
0 · Reply
Latest News on RXRX
Recursion Pharmaceuticals, Inc. (RXRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 6, 2026, 12:35 PM EST - 9 days ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript

Feb 25, 2026, 12:47 PM EST - 18 days ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 25, 2026, 6:30 AM EST - 18 days ago

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC

Feb 23, 2026, 8:00 AM EST - 20 days ago

Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC

Recursion to Participate in Upcoming Investor Conferences

Feb 23, 2026, 7:55 AM EST - 20 days ago

Recursion to Participate in Upcoming Investor Conferences

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Feb 18, 2026, 8:30 AM EST - 25 days ago

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia.

Feb 18, 2026, 5:43 AM EST - 25 days ago

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia.

APLD NVDA

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript

Jan 22, 2026, 2:54 PM EST - 7 weeks ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 5:46 PM EST - 2 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:59 AM EST - 2 months ago

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

3 Small AI Plays to Buy for 2026

Dec 26, 2025, 1:28 PM EST - 2 months ago

3 Small AI Plays to Buy for 2026

ANET INOD

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

Dec 18, 2025, 11:38 AM EST - 3 months ago

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

What's Happening With RXRX Stock?

Dec 18, 2025, 11:05 AM EST - 3 months ago

What's Happening With RXRX Stock?

Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

Dec 8, 2025, 4:37 PM EST - 3 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Dec 8, 2025, 7:32 AM EST - 3 months ago

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Dec 8, 2025, 7:30 AM EST - 3 months ago

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Dec 5, 2025, 8:19 AM EST - 3 months ago

Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Dec 1, 2025, 8:30 AM EST - 3 months ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 21, 2025, 7:43 PM EST - 4 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Nov 18, 2025, 10:14 AM EST - 4 months ago

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 8:11 PM EST - 4 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 6:30 AM EST - 4 months ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Nov 5, 2025, 6:28 AM EST - 4 months ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Oct 28, 2025, 8:00 AM EDT - 4 months ago

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

Oct 22, 2025, 1:42 PM EDT - 5 months ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS IBRX PLUG RKT

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Oct 8, 2025, 2:51 PM EDT - 5 months ago

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 8:03 PM EDT - 6 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 6:51 PM EDT - 6 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 2:44 PM EDT - 7 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 6:30 AM EDT - 7 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jul 29, 2025, 8:00 AM EDT - 8 months ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

Jul 25, 2025, 1:53 PM EDT - 8 months ago

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

NVDA PLTR

Top 2 Health Care Stocks You May Want To Dump This Quarter

Jul 22, 2025, 7:02 AM EDT - 8 months ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

MEDP

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 10, 2025, 6:14 AM EDT - 9 months ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Jun 6, 2025, 10:00 AM EDT - 10 months ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 1:37 PM EDT - 11 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 6:00 AM EDT - 11 months ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

May 5, 2025, 4:02 AM EDT - 11 months ago

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

May 4, 2025, 12:45 PM EDT - 11 months ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 28, 2025, 8:27 AM EDT - 11 months ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 22, 2025, 8:34 PM EDT - 11 months ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 16, 2025, 8:30 AM EDT - 11 months ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion to Participate in Upcoming Investor Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Recursion to Participate in Upcoming Investor Conference

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Mar 3, 2025, 11:19 AM EST - 1 year ago

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 1:16 PM EST - 1 year ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 28, 2025, 6:30 AM EST - 1 year ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 24, 2025, 8:00 AM EST - 1 year ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Altitude Lab Startups Raise $154M in Capital

Feb 18, 2025, 11:00 AM EST - 1 year ago

Altitude Lab Startups Raise $154M in Capital

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Feb 13, 2025, 6:05 PM EST - 1 year ago

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Bazzzigar
Bazzzigar Mar. 15 at 8:06 PM
$RXRX HIMS
0 · Reply
DragonAlgo
DragonAlgo Mar. 15 at 2:36 AM
🐉 $RXRX CALL — DragonAlgo® Signal Contract: RXRX CALL Expiry: 2026-04-17 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $0.17 Stop: $0.12 TP1: $0.22 TP2: $0.29 TP3: $0.41 🔗 https://dragonalgo.com
0 · Reply
MakingMoney20
MakingMoney20 Mar. 14 at 5:01 PM
$RXRX Looking to this spring for some great gains as Summer comes to heat things up! Want a watch this Bust out! Recursion! RXRX $$
0 · Reply
JennyRowes
JennyRowes Mar. 14 at 3:26 PM
$GENB $ABSI $RXRX which AI drug dev leader do we think has more chops?? A) Najat Kahn B) Sean McCain C) Mike Nally
0 · Reply
cntrade1
cntrade1 Mar. 14 at 2:12 AM
$RXRX Vanguard scooped up over 3.7 million RXRX shares in Q3 last year, pushing them to about forty million total. ARK added half a million + in that same quarter. They also added another ~1.3 million in February alone.
1 · Reply
Spartangio
Spartangio Mar. 13 at 10:37 PM
$RXRX NVIDIA — Insider Selling History $3.4 BILLION sold by insiders. 161 Form 4s. All sales. Zero buys. For years. Stock: +10,000% 🚀 RXRX bears crying about $5M insider sales
0 · Reply
Brodman
Brodman Mar. 13 at 9:30 PM
$RXRX There are a LOT OF INSIDERS SELLING….A LOT??? That along with Nvidia dumping shares a huge Red Flag…It may be time to get out of Dodge before it really bottoms out. ITS GOING MUCH LOWER!!!!
2 · Reply
Zio_Fauss
Zio_Fauss Mar. 13 at 8:35 PM
$RXRX These doctors and half-baked scientists are sucking up money every month. https://ir.recursion.com/financials-filings/sec-filings?field_nir_sec_date_filed_value=2026&filter_type=&relative_date_range_after=&relative_date_range_before=&exact_date_range_after=&exact_date_range_before=&items_per_page=50#views-exposed-form-widget-sec-filings-table
0 · Reply
cntrade1
cntrade1 Mar. 13 at 8:10 PM
$RXRX
0 · Reply
cntrade1
cntrade1 Mar. 13 at 7:21 PM
$RXRX Recursion’s got a solid lineup of catalysts ahead, NVIDIA GTC next week (March 16-19) talking AI drug labs, early Phase 1 safety/PK updates rolling out: REC-1245 (RBM39 degrader) in the first half, others like REC-617 and REC-3565 into next year.
0 · Reply
cntrade1
cntrade1 Mar. 13 at 7:10 PM
$RXRX great buy/hold imo 💎
0 · Reply
dwche
dwche Mar. 13 at 7:09 PM
$RXRX Is the algos stopped working. Its circling 2 cents up & down?
0 · Reply
theRockSeys
theRockSeys Mar. 13 at 7:08 PM
$RXRX that’s a buy signal to me. Because he recommended it in the past and yes when it was like $30+ share that was ridiculous. Now is the time to buy, at all time lows, especially when phase 2 was a success and nearing FDA approval.
0 · Reply
_dailyBULLetin
_dailyBULLetin Mar. 13 at 6:05 PM
$DJT $RXRX $EOSE $TLYS &
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 13 at 5:52 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
WilliamWeber629
WilliamWeber629 Mar. 13 at 5:33 PM
$RXRX biotechnology company using artificial intelligence for drug discovery 30
0 · Reply
Lastaccountgotbannedd
Lastaccountgotbannedd Mar. 13 at 4:39 PM
$RXRX I can’t find the REC-4539 phase 1/2 trial on http://clinicaltrials.gov. Does anyone have any updates? Last update was January 2025 lol
1 · Reply
DragonAlgo
DragonAlgo Mar. 13 at 4:05 PM
🐉 $RXRX CALL — DragonAlgo® Signal Contract: RXRX CALL Expiry: 2026-03-20 | Strike: $3.50 | Type: CALL Option Plan (premium): Entry: $0.11 Stop: $0.08 TP1: $0.15 TP2: $0.20 TP3: $0.28 🔗 https://dragonalgo.com
0 · Reply
Brodman
Brodman Mar. 13 at 3:45 PM
$RXRX Cramer crushes RXRX again and Nvidia dumping tells you where this is going....no where!!! Just pissing money away here. https://finance.yahoo.com/news/jim-cramer-recursion-pharmaceuticals-let-151633045.html
1 · Reply
Tobitski
Tobitski Mar. 13 at 2:31 PM
$RXRX lord I forgot the bullish sign 🙈😅
0 · Reply
cntrade1
cntrade1 Mar. 13 at 2:31 PM
$RXRX 💪 💎
0 · Reply
Tobitski
Tobitski Mar. 13 at 2:30 PM
$RXRX 🌳👀🌳 Nvidea conferance coming up. Could be fun ….💣
0 · Reply